ARLINGTON, Mass. — May 7, 2026 — Leads & Copy — KALA BIO, Inc. (NASDAQ: KALA) plans to implement a reverse stock split of its common stock at a ratio of 1-for-50, effective May 8, 2026, at 4:05 p.m., the company announced today.
The company’s stock will continue to trade on the Nasdaq Capital Market under the ticker symbol KALA, beginning on a split-adjusted basis when the market opens on Monday, May 11, 2026. The new CUSIP number for the common stock following the reverse stock split is 483119301.
At a special meeting of stockholders held January 30, 2026, the Company’s stockholders granted the Board of Directors discretion to effect a reverse stock split via an amendment to its Restated Certificate of Incorporation, as amended, at a ratio of not less than 1-for-2 and not more than 1-for-100, with the ratio determined by the Board.
At the effective time, every 50 shares of issued and outstanding common stock will be converted automatically into one share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares adjusted automatically to reflect the 1-for-50 reverse stock split. Stockholders holding shares of common stock in certificated form are not required to exchange their existing stock certificates for new stock certificates, although they may do so if desired.
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares will be issued. Stockholders that would hold fractional shares as a result of the split are entitled to receive a cash payment in lieu of said fractional shares based on the closing price on the Nasdaq Capital Market on May 7, 2026.
The reverse stock split will reduce the number of shares of the Company’s common stock outstanding from 929,491,578 shares to approximately 18,589,832 shares. Proportional adjustments will be made to the number of shares of the Company’s common stock issuable upon exercise or conversion of the Company’s equity awards, warrants and other convertible securities, as well as the applicable exercise or conversion price thereof.
Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker. All other stockholders may direct questions to the Company’s transfer agent, Equiniti Trust Company, LLC, at (929) 469-2386.
Kala BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company’s dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.
Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows.
The Company’s focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector. Kala believes the future of biomedical innovation is in agentic systems.
Source: KALA BIO, Inc.
